GSK in $150m US settlement

GlaxoSmithKline has reached a $150m (£92m) preliminary settlement with US drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, according to court documents.

The settlement was reached with, among others, AmerisourceBergen, Cardinal Health and McKesson Corp, who maintained that Glaxo had abused the citizen's petition process to maintain a market monopoly.